drugset

drugset / Trial / NCT05038657

Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).

NCT05038657 ↗

Phase 2 Unknown 36 enrolled University Hospital Southampton NHS Foundation Trust Cancer Research UK · collab Roche Pharma AG · collab

NaSingle-groupOpen-labelTreatment

Summary

Atezolizumab in patients with urinary tract squamous cell carcinoma: a single-arm, open-label, multicentre, phase II clinical trial

Timeline

Start: 2022-05-30
Primary completion: 2024-01
Completion: 2025-01

Publications

Crabb S, Wickens R, Jane-Bibby S, Dunkley D, Lawrence M, Knight A, Jones R, Birtle A, Huddart R, Linch M, Martin J, Coleman A, Boukas K, Markham H, Griffiths G. Evaluating atezolizumab in patients with urinary tract squamous cell carcinoma (AURORA): study protocol for a single arm, open-label, multicentre, phase II clinical trial. BMC Cancer. 2023 Sep 19;23(1):885. doi: 10.1186/s12885-023-11397-x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atezolizumab	Monoclonal antibody	1680 mg	Intravenous

Indications